However, the combination of GNP-LLO91-99 with anti-PD-1 and anti-CTLA-4 antibodies resulted in synergistic efficacy and complete tumor regression (90) Of note, the melanoma model in this study, B16F10, is performed in the H2b-restricted C57BL/6 mice while the LLO-derived peptide within GNP-LLO91-99 is well characterized as an H2Kd-restricted LLO epitope suggesting further investigation is warranted to fully understand its mechanism(s) of adjuvancy. This evidence concerns the gene CTLA4 and neoplasm.